A Phase 4 interventional study of Fluticasone propionate/salmeterol (FS) and Albuterol in Asthma, sponsored by Teva Branded Pharmaceutical Products R&D, Inc.. Completed at 46 sites in United States. Open to participants aged 13 Years and older. Per ClinicalTrials.gov, last updated 2023-03-14.
Sponsored by Teva Branded Pharmaceutical Products R&D, Inc. (part of Teva Pharmaceutical Industries, Ltd.) · Phase 4, Interventional, and Treatment
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
Among 147 studies testing fluticasone in Asthma — 1 open to participants now, 4 under way, 2 of them phase 3. Fluticasone · Asthma.
Among the 147 studies testing fluticasone in Asthma, this one is the 40th largest by enrollment of the 146 interventional ones that give a count, is one of 5 that started in 2021, is one of 52 in phase 4, and was the 137th registered.
4,848 studies on the registry are indexed under Asthma; 605 are open to participants now.
Browse Asthma studies →1 of the 147 studies testing fluticasone in Asthma is open now, in 1 country. Recruiting first, the newest first:
University of Wisconsin, Madison · Sites in United States
Ages 18+ · Healthy volunteers
By country, each count listing its studies:
Fluticasone: first FDA approval 1990 (CUTIVATE), first EMA approval 2008. What it is approved for, and how studies give it, is on its page →
Of the 417 Asthma studies recruiting now, 140 (34%) set no upper age limit and 205 (49%) stop at 75 or younger; 147 take children under 18; 105 take healthy volunteers.
This study: 13 Years and older · all sexes · no healthy volunteers.
The full table on the hub →This tab as a report to print or save as PDF → With an account.
147 studies; the count open now beside each. This study's row is marked.
First in 1999; this study’s year is marked. 5 started in 2021.
By drug class, each counting the studies that test any of its medicines:
This study's enrollment of 427 is above the median of 79 across 3,344 interventional studies indexed under Asthma.
Median enrollment 100 across the 146 interventional studies. Of the 130 that completed or were terminated, 68 (52%) have results posted.
This tab as a report to print or save as PDF → With an account.
107 of 147 have an industry lead sponsor. The 10 most frequent:
This study is registered under Teva Branded Pharmaceutical Products R&D, Inc., one of the names counted as Teva Pharmaceutical Industries, Ltd.. Under that name alone:
Teva Branded Pharmaceutical Products R&D, Inc. is the lead sponsor of 206 studies on the registry; none are open to participants now.
Of its 49 completed or terminated interventional studies of FDA-regulated products, 47 (96%) have results posted.
54 studies in Asthma by Teva Pharmaceutical Industries, Ltd.: none open now, 1 under way, 1 of them phase 3. Of 52 finished, 36 (69%) have results posted.
Among the 54 studies in Asthma by Teva Pharmaceutical Industries, Ltd., this one is the 19th largest by enrollment of the 51 interventional ones that give a count, is one of 2 that started in 2021, is one of 6 in phase 4, and was the 50th registered.
Teva Pharmaceutical Industries, Ltd.’s Asthma studies by the year they started, since 2003.
2 of the studies testing fluticasone in Asthma that are under way reach primary completion within a year, 1 of them phase 3. Phase 3 first, then by date:
| Study | Primary completion |
|---|---|
| NCT05757102Phase 3GlaxoSmithKlineA Study to Compare the Efficacy, Safety and Tolerability of FF/UMEC/VI With FF/VI in 12-17-year-olds With Asthma | 2027-01-26 |
| NCT07664527University of Wisconsin, MadisonNovel Method for Removal of Orally Deposited Inhaled Fluticasone Propionate | 2027-09 |
Add all 2 to your calendar (.ics) → With an account.
Among the 147 studies testing fluticasone in Asthma, from their registry updates:
Among Teva Pharmaceutical Industries, Ltd.’s 54 in Asthma:
This tab as a report to print or save as PDF → With an account.
The primary objective of this study is to demonstrate the effectiveness of the Digital System (DS) in improving asthma control compared to the Standard of Care (SoC) group.
The secondary objective is to describe the asthma management actions by investigational center health care providers (iHCPs) for all participants in both groups, to evaluate short-acting beta2 agonist (SABA) usage and the number of SABA-free days in the DS group, to evaluate adherence patterns to maintenance treatment (FS eMDPI) in the DS group, to assess behavioral correlates of responsiveness to digital health technology among participants for all participants in both groups, to evaluate work productivity and activity impairment in asthma participants in both groups, to assess the usability and acceptability of the DS by participants in the DS group and the investigational center personnel, and to evaluate the safety of FS eMDPI and Albuterol eMDPI.
Study duration will be approximately 27 weeks including a one-week screening period, 24 week treatment period, and a 2 week follow-up period.
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
The participant is willing to discontinue all other maintenance ICS with LABA medications and rescue medications and replace them with the study-provided fluticasone propionate/salmeterol (FS) multidose dry powder inhaler with integrated electronic module (eMDPI) and Albuterol eMDPI, respectively, for the duration of the trial, if randomized to the Digital System group. All other asthma maintenance medications, except for ICS with LABA, may be continued.
Exclusion Criteria:
The participant has any medical or psychiatric condition that, in the opinion of the investigator, could jeopardize or would compromise the patient's ability to participate in this study.
Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
A drug or device being studied in a clinical trial.
It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.
Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.
You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.
Anti-inflammatory medicines such as prednisone, prednisolone and dexamethasone — not the anabolic steroids used for muscle.
Studies differ in what they allow: check which steroid medicines, routes (tablets, injections, creams, inhalers, eye drops) and doses this study accepts.
Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.
Investigational drug or device
A drug or device being studied in a clinical trial.
It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Informed consent
Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.
You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Corticosteroids (steroids)
Anti-inflammatory medicines such as prednisone, prednisolone and dexamethasone — not the anabolic steroids used for muscle.
Studies differ in what they allow: check which steroid medicines, routes (tablets, injections, creams, inhalers, eye drops) and doses this study accepts.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Clinically significant
Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
DS group participants utilizing the eMDPI DS, including inhaler, smart device application (App), DHP (Cloud solution), and dashboard
Drug: Fluticasone propionate/salmeterol (FS) · Drug: Albuterol
SoC group participants will be treated with their standard of care medications
Drug: Standard of Care Asthma Medication · Drug: Standard of Care Rescue Medication
Drug pages: Fluticasone · Salmeterol Xinafoate
FS administered via electronic multidose dry powder inhaler (eMDPI) Digital System (DS) with component devices including smart device application (App), Digital Health Platform (DHP), and provider-facing dashboard
Albuterol administered via electronic multidose dry powder inhaler (eMDPI) Digital System (DS) with component devices including smart device application (App), Digital Health Platform (DHP), and provider-facing dashboard
Current inhaled corticosteroid(ICS)/Long-acting beta agonist(LABA) and any additional controller medication for asthma
Current rescue medication
Number of Participants Achieving Well-Controlled Asthma or Reaching Clinically Important Improvement in Asthma Control
A well-controlled asthma was defined as an Asthma Control Test (ACT) score of greater than or equal to 20. Clinically important improvement in asthma control was defined by an increase of at least 3 ACT units from baseline. The ACT was a simple, participant-completed tool used for the assessment of overall asthma control. The ACT included 5 items that assessed daytime and nighttime asthma symptoms, use of reliever medication, and impact of asthma on daily functioning. Each item in the ACT was scored on a 5-point scale ranging from 1 (poor control of asthma) to 5 (well control of asthma), with summation of all items providing scores ranging from 5 to 25. The scores span the continuum of poor control of asthma (score of 5) to complete control of asthma (score of 25), with a cutoff score of 19 and below indicating participants with poorly controlled asthma.
Time frame: Week 24
Number of Discussions Between Participant and Investigational Center Healthcare Professional (iHCP) Regarding Inhaler Technique or Adherence
Number of participants who had discussions with iHCP regarding inhaler technique or adherence are reported.
Time frame: Baseline up to Week 24
Number of Decreased Doses of Inhaled Medication
Number of participants who received decreased dose of inhaled medication during the 24-week treatment period are reported.
Time frame: Baseline up to Week 24
Number of Increased Doses of Inhaled Medication
Number of participants who received increased dose of inhaled medication during the 24-week treatment period are reported.
Time frame: Baseline up to Week 24
Number of Changes to Different Inhaled Medication
Number of participants who received different inhaled medication during the 24-week treatment period are reported.
Time frame: Baseline up to Week 24
Number of Additional Inhaled Medication
Number of participants who received additional inhaled medication during the 24-week treatment period are reported.
Time frame: Baseline up to Week 24
Number of Addition of a Systemic Corticosteroid Medication for Asthma Therapy
Number of participants who received additional systemic corticosteroid medication for asthma therapy during the 24-week treatment period are reported.
Time frame: Baseline up to Week 24
Frequency of Intervention to Manage Comorbid Conditions Associated With Poor Asthma Control
Number of participants with different frequency of intervention to manage comorbid conditions such as Gastroesophageal Reflux Disease (GERD) and Sinusitis are reported.
Time frame: Baseline up to Week 24
Change From Baseline in Mean Weekly SABA Usage at Week 24 for the DS Group
Time frame: Baseline, Week 24
Change From Baseline in the Number of SABA-free Days at Week 24 for the DS Group
Number of days a participant did not use the rescue medication in a week are reported.
Time frame: Baseline, Week 24
Change From Baseline in Adherence to Maintenance Treatment (FS eMDPI) at Week 24 for the DS Group
Adherence to maintenance treatment was defined as the percentage of actual inhalation doses taken out of the total number of inhalation doses prescribed over the 24- week treatment period.
Time frame: Baseline, Week 24
Change From Baseline in Beliefs About Medicines Questionnaire (BMQ) Concern Subscale Score at Week 24
The BMQ was used to assess cognitive representations of medicine. The Beliefs About Medicines Questionnaire-Specific 11 (BMQ-S11) was an 11-item questionnaire that assessed the representation of medication prescribed for personal use and the BMQ-General assesses beliefs about medicines in general. BMQ concern is a 6-item scale assessing participant's concerns about potential adverse consequences (range: 1=strongly disagree to 5=strongly agree). Participants indicated their degree of agreement on a 5-point scale, ranging from 1=strongly disagree to 5=strongly agree. Scores obtained for individual items were summed, divided by the total number of items and multiplied by 5 to give a total score ranging from 5 to 25 (higher scores=stronger beliefs).
Time frame: Baseline, Week 24
Change From Baseline in BMQ Necessity Subscale Score at Week 24
The BMQ was used to assess cognitive representations of medicine. The Beliefs About Medicines Questionnaire-Specific 11 (BMQ-S11) was an 11-item questionnaire that assessed the representation of medication prescribed for personal use and the BMQ-General assesses beliefs about medicines in general. BMQ necessity is a 5-item scale assessing participant's beliefs about necessity of medications for controlling disease. Participants indicated degree of agreement on a 5-point scale, ranging from 1=strongly disagree to 5=strongly agree. Scores obtained for individual items were summed, divided by the total number of items and multiplied by 5 to give a total score ranging from 5 to 25 (higher scores=stronger beliefs).
Time frame: Baseline, Week 24
Change From Baseline in Brief Illness Perception Questionnaire (BIPQ) Illness Comprehensibility Subscale Score at Week 24
The BIPQ was a 9-item questionnaire designed to rapidly assess cognitive and emotional representations of illness. Only one item assesses illness comprehensibility or coherence of illness (Item 7: How well do you feel you understand your illness?). This item was rated using a 0 (do not understand at all) to 10 (understand very clearly) response scale. A higher score indicates a stronger illness comprehensibility.
Time frame: Baseline, Week 24
Change From Baseline in BIPQ Cognitive Subscale Score at Week 24
BIPQ was a 9-item questionnaire designed to rapidly assess cognitive and emotional representations of illness. It comprised 5 items on cognitive representation of illness perception: consequences (Item 1: How much does your illness affect your life? Response range 0 \[no affect\] - 10 \[severe affect\]), timeline (Item 2: How long do you think your illness will continue? Response range 0 \[a very short time\] - 10 \[forever\]), personal control (Item 3: How much control do you feel you have over your illness? Response range 0 \[no control\] - 10 \[extreme amount of control\]), treatment control (Item 4: How much do you think your treatment can help your illness? Response range 0 \[not at all\] - 10 \[extremely helpful\]), and identity (Item 5: How much do you experience symptoms from your illness? Response range 0 \[no symptoms\] - 10 \[severe symptoms\]). Total BIPQ Cognitive Subscale Score was the sum of all item score and ranged from 0 to 50. A higher score indicates stronger illness perception.
Time frame: Baseline, Week 24
Change From Baseline in BIPQ Emotional Representations Subscale Score at Week 24
BIPQ was a 9-item questionnaire designed to rapidly assess cognitive and emotional representations of illness. It comprised 2 items on emotional representation: concern (Item 6: How concerned are you about your illness? Response range 0 \[not at all concerned\] - 10 \[extremely concerned\]) and emotions (Item 8: How much does your illness affect you emotionally; for example, does it make you angry, scared, upset or depressed? Response range 0 \[not at all affected emotionally\] - 10 \[extremely affected emotionally\]). Total BIPQ Emotional Subscale Score was the sum of above 2 items score and ranged from 0 to 20. A higher score indicates extreme emotional representation.
Time frame: Baseline, Week 24
Change From Baseline in Work Productivity and Activity Impairment (WPAI) Asthma Questionnaire Score at Week 24
WPAI-asthma is a self-administered instrument to measure asthma-specific performance impairment of work and regular daily activity within the last 7 days and yields 4 types of scores: work time missed (absenteeism), impairment while working (presenteeism or reduced on-the-job effectiveness), overall work impairment (WI) (work productivity loss or absenteeism plus presenteeism) and activity impairment (daily activity impairment). Total score and each score ranged from 0 (not affected/no impairment) to 100 (completely affected/impaired). Higher scores indicated greater impairment and less productivity.
Time frame: Baseline, Week 24
System Usability Scale (SUS) Overall Score for DS Group
The SUS was used to explore device acceptability and usability for participants in the DS group. It covered a variety of aspects of system usability, such as the need for support, training, and complexity, and thus giving a global view of subjective assessments of usability. It was a 10-question tool (with five response options; from 1=strongly disagree to 5=strongly agree) that provided a composite measure, ranging from 0 to 100, of the overall usability of the system being studied. Higher scores represent better usability level for the tool.
Time frame: Week 24
Number of Participants With Adverse Events (AEs)
An AE was defined as any untoward medical occurrence that develops or worsens in severity during the conduct of a clinical study and does not necessarily have a causal relationship to the study drug. SAEs included death, a life-threatening adverse event, inpatient hospitalization or prolongation of existing hospitalization, persistent or significant disability or incapacity, a congenital anomaly or birth defect, or an important medical event that jeopardized the participant and required medical intervention to prevent 1 of the outcomes listed in this definition. A summary of serious and non-serious AEs regardless of causality is located in 'Reported Adverse Events module'. Number of participants with any AEs, and device-related AEs has been reported.
Time frame: Baseline up to Week 26
| Milestone | Standard of Care (SoC) | Digital System (DS) |
|---|---|---|
| Started | 185 | 242 |
| Safety analysis set | 185 | 224 |
| Completed | 173 | 183 |
| Not completed | 12 | 59 |
| Withdrew: Adverse event | 1 | 9 |
| Withdrew: Withdrawal by subject | 2 | 15 |
| Withdrew: Withdrawal by parent/guardian | 0 | 1 |
| Withdrew: Non-compliance with study drug | 0 | 2 |
| Withdrew: Protocol deviation | 0 | 11 |
| Withdrew: Lost to follow-up | 9 | 13 |
| Withdrew: Other than specified | 0 | 8 |
A well-controlled asthma was defined as an Asthma Control Test (ACT) score of greater than or equal to 20. Clinically important improvement in asthma control was defined by an increase of at least 3 ACT units from baseline. The ACT was a simple, participant-completed tool used for the assessment of overall asthma control. The ACT included 5 items that assessed daytime and nighttime asthma symptoms, use of reliever medication, and impact of asthma on daily functioning. Each item in the ACT was scored on a 5-point scale ranging from 1 (poor control of asthma) to 5 (well control of asthma), with summation of all items providing scores ranging from 5 to 25. The scores span the continuum of poor control of asthma (score of 5) to complete control of asthma (score of 25), with a cutoff score of 19 and below indicating participants with poorly controlled asthma.
| Participants | Standard of Care (SoC) | Digital System (DS) |
|---|---|---|
| Number of Participants Achieving Well-Controlled Asthma or Reaching Clinically Important Improvement in Asthma Control | 112 | 134 |
Number of participants who had discussions with iHCP regarding inhaler technique or adherence are reported.
| Participants | Standard of Care (SoC) | Digital System (DS) |
|---|---|---|
| 0 discussion | 90 | 55 |
| 1 discussion | 33 | 38 |
| 2 discussions | 50 | 55 |
| 3 discussions | 4 | 9 |
| 4 discussions | 0 | 14 |
| 5 discussions | 1 | 4 |
| 6 discussions | 0 | 4 |
| 7 discussions | 0 | 1 |
| 8 discussions | 0 | 6 |
| 10 discussions | 0 | 5 |
| 12 discussions | 0 | 2 |
| 13 discussions | 0 | 1 |
| 14 discussions | 0 | 1 |
| 15 discussions | 0 | 1 |
| 16 discussions | 0 | 1 |
| 17 discussions | 0 | 1 |
| 18 discussions | 0 | 1 |
| 19 discussions | 0 | 4 |
| 20 discussions | 0 | 1 |
| 21 discussions | 0 | 2 |
| 22 discussions | 0 | 1 |
| 23 discussions | 0 | 1 |
| 26 discussions | 0 | 1 |
| 29 discussions | 0 | 1 |
Number of participants who received decreased dose of inhaled medication during the 24-week treatment period are reported.
| Participants | Standard of Care (SoC) | Digital System (DS) |
|---|---|---|
| Number of Decreased Doses of Inhaled Medication | 0 | 0 |
Number of participants who received increased dose of inhaled medication during the 24-week treatment period are reported.
| Participants | Standard of Care (SoC) | Digital System (DS) |
|---|---|---|
| No increased doses | 173 | 200 |
| 1 increased dose | 5 | 10 |
Number of participants who received different inhaled medication during the 24-week treatment period are reported.
| Participants | Standard of Care (SoC) | Digital System (DS) |
|---|---|---|
| No change to different inhaled medication | 175 | 187 |
| 1 change to different inhaled medication | 3 | 23 |
Number of participants who received additional inhaled medication during the 24-week treatment period are reported.
| Participants | Standard of Care (SoC) | Digital System (DS) |
|---|---|---|
| No additional inhaled medication | 173 | 206 |
| 1 additional inhaled medication | 4 | 4 |
| 2 additional inhaled medications | 1 | 0 |
Number of participants who received additional systemic corticosteroid medication for asthma therapy during the 24-week treatment period are reported.
| Participants | Standard of Care (SoC) | Digital System (DS) |
|---|---|---|
| No addition of a systemic corticosteroid medication for asthma therapy | 173 | 201 |
| 1 addition of a systemic corticosteroid medication for asthma therapy | 3 | 7 |
| 2 addition of a systemic corticosteroid medications for asthma therapy | 0 | 1 |
| 3 addition of a systemic corticosteroid medications for asthma therapy | 2 | 1 |
Number of participants with different frequency of intervention to manage comorbid conditions such as Gastroesophageal Reflux Disease (GERD) and Sinusitis are reported.
| Participants | Standard of Care (SoC) | Digital System (DS) |
|---|---|---|
| No intervention to manage comorbid conditions | 169 | 199 |
| Interventions taken 1 time to manage comorbid conditions | 7 | 7 |
| Interventions taken 2 times to manage comorbid conditions | 2 | 4 |
| micrograms (μg) | Digital System (DS) |
|---|---|
| Change From Baseline in Mean Weekly SABA Usage at Week 24 for the DS Group | -12.26 ± 59.199 |
Number of days a participant did not use the rescue medication in a week are reported.
| days | Digital System (DS) |
|---|---|
| Change From Baseline in the Number of SABA-free Days at Week 24 for the DS Group | 0.4 ± 1.94 |
Adherence to maintenance treatment was defined as the percentage of actual inhalation doses taken out of the total number of inhalation doses prescribed over the 24- week treatment period.
| percentage of inhalation | Digital System (DS) |
|---|---|
| Change From Baseline in Adherence to Maintenance Treatment (FS eMDPI) at Week 24 for the DS Group | -10.87 ± 31.717 |
The BMQ was used to assess cognitive representations of medicine. The Beliefs About Medicines Questionnaire-Specific 11 (BMQ-S11) was an 11-item questionnaire that assessed the representation of medication prescribed for personal use and the BMQ-General assesses beliefs about medicines in general. BMQ concern is a 6-item scale assessing participant's concerns about potential adverse consequences (range: 1=strongly disagree to 5=strongly agree). Participants indicated their degree of agreement on a 5-point scale, ranging from 1=strongly disagree to 5=strongly agree. Scores obtained for individual items were summed, divided by the total number of items and multiplied by 5 to give a total score ranging from 5 to 25 (higher scores=stronger beliefs).
| units on a scale | Standard of Care (SoC) | Digital System (DS) |
|---|---|---|
| Change From Baseline in Beliefs About Medicines Questionnaire (BMQ) Concern Subscale Score at Week 24 | -0.8 ± 3.34 | -0.9 ± 4.06 |
The BMQ was used to assess cognitive representations of medicine. The Beliefs About Medicines Questionnaire-Specific 11 (BMQ-S11) was an 11-item questionnaire that assessed the representation of medication prescribed for personal use and the BMQ-General assesses beliefs about medicines in general. BMQ necessity is a 5-item scale assessing participant's beliefs about necessity of medications for controlling disease. Participants indicated degree of agreement on a 5-point scale, ranging from 1=strongly disagree to 5=strongly agree. Scores obtained for individual items were summed, divided by the total number of items and multiplied by 5 to give a total score ranging from 5 to 25 (higher scores=stronger beliefs).
| units on a scale | Standard of Care (SoC) | Digital System (DS) |
|---|---|---|
| Change From Baseline in BMQ Necessity Subscale Score at Week 24 | -0.4 ± 3.27 | -1.3 ± 3.86 |
The BIPQ was a 9-item questionnaire designed to rapidly assess cognitive and emotional representations of illness. Only one item assesses illness comprehensibility or coherence of illness (Item 7: How well do you feel you understand your illness?). This item was rated using a 0 (do not understand at all) to 10 (understand very clearly) response scale. A higher score indicates a stronger illness comprehensibility.
| units on a scale | Standard of Care (SoC) | Digital System (DS) |
|---|---|---|
| Change From Baseline in Brief Illness Perception Questionnaire (BIPQ) Illness Comprehensibility Subscale Score at Week 24 | -0.0 ± 1.65 | 0.1 ± 2.04 |
BIPQ was a 9-item questionnaire designed to rapidly assess cognitive and emotional representations of illness. It comprised 5 items on cognitive representation of illness perception: consequences (Item 1: How much does your illness affect your life? Response range 0 \[no affect\] - 10 \[severe affect\]), timeline (Item 2: How long do you think your illness will continue? Response range 0 \[a very short time\] - 10 \[forever\]), personal control (Item 3: How much control do you feel you have over your illness? Response range 0 \[no control\] - 10 \[extreme amount of control\]), treatment control (Item 4: How much do you think your treatment can help your illness? Response range 0 \[not at all\] - 10 \[extremely helpful\]), and identity (Item 5: How much do you experience symptoms from your illness? Response range 0 \[no symptoms\] - 10 \[severe symptoms\]). Total BIPQ Cognitive Subscale Score was the sum of all item score and ranged from 0 to 50. A higher score indicates stronger illness perception.
| units on a scale | Standard of Care (SoC) | Digital System (DS) |
|---|---|---|
| Change From Baseline in BIPQ Cognitive Subscale Score at Week 24 | -2.5 ± 5.51 | -3.3 ± 6.83 |
BIPQ was a 9-item questionnaire designed to rapidly assess cognitive and emotional representations of illness. It comprised 2 items on emotional representation: concern (Item 6: How concerned are you about your illness? Response range 0 \[not at all concerned\] - 10 \[extremely concerned\]) and emotions (Item 8: How much does your illness affect you emotionally; for example, does it make you angry, scared, upset or depressed? Response range 0 \[not at all affected emotionally\] - 10 \[extremely affected emotionally\]). Total BIPQ Emotional Subscale Score was the sum of above 2 items score and ranged from 0 to 20. A higher score indicates extreme emotional representation.
| units on a scale | Standard of Care (SoC) | Digital System (DS) |
|---|---|---|
| Change From Baseline in BIPQ Emotional Representations Subscale Score at Week 24 | -1.1 ± 4.01 | -1.3 ± 3.98 |
WPAI-asthma is a self-administered instrument to measure asthma-specific performance impairment of work and regular daily activity within the last 7 days and yields 4 types of scores: work time missed (absenteeism), impairment while working (presenteeism or reduced on-the-job effectiveness), overall work impairment (WI) (work productivity loss or absenteeism plus presenteeism) and activity impairment (daily activity impairment). Total score and each score ranged from 0 (not affected/no impairment) to 100 (completely affected/impaired). Higher scores indicated greater impairment and less productivity.
| units on a scale | Standard of Care (SoC) | Digital System (DS) |
|---|---|---|
| Absenteeism | -3.56 ± 14.38 | -0.05 ± 8.61 |
| Presenteeism | -10.98 ± 24.50 | -10.43 ± 18.57 |
| Work productivity loss | -12.18 ± 26.25 | -9.87 ± 19.16 |
| Activity impairment | -11.22 ± 23.81 | -15.33 ± 21.48 |
The SUS was used to explore device acceptability and usability for participants in the DS group. It covered a variety of aspects of system usability, such as the need for support, training, and complexity, and thus giving a global view of subjective assessments of usability. It was a 10-question tool (with five response options; from 1=strongly disagree to 5=strongly agree) that provided a composite measure, ranging from 0 to 100, of the overall usability of the system being studied. Higher scores represent better usability level for the tool.
| units on a scale | Digital System (DS) |
|---|---|
| SUS Overall Score (completed by participants) | 70.0 ± 19.10 |
| Site SUS Overall Score (completed by site) | 73.2 ± 18.03 |
An AE was defined as any untoward medical occurrence that develops or worsens in severity during the conduct of a clinical study and does not necessarily have a causal relationship to the study drug. SAEs included death, a life-threatening adverse event, inpatient hospitalization or prolongation of existing hospitalization, persistent or significant disability or incapacity, a congenital anomaly or birth defect, or an important medical event that jeopardized the participant and required medical intervention to prevent 1 of the outcomes listed in this definition. A summary of serious and non-serious AEs regardless of causality is located in 'Reported Adverse Events module'. Number of participants with any AEs, and device-related AEs has been reported.
| Participants | Standard of Care (SoC) | Digital System (DS) |
|---|---|---|
| Any AEs | 56 | 77 |
| Device-related AEs | 0 | 3 |
Collected over Baseline up to Week 26. Non-serious events are listed at a 5% frequency threshold.
| Group | Deaths | Serious | Other |
|---|---|---|---|
| Standard of Care (SoC) | 0/185 (0%) | 4/185 (2.2%) | 23/185 (12.4%) |
| Digital System (DS) | 0/224 (0%) | 6/224 (2.7%) | 24/224 (10.7%) |
| Event | Standard of Care (SoC) | Digital System (DS) |
|---|---|---|
| Coronary artery diseaseCardiac disorders | 1/185 | 0/224 |
| PancreatitisGastrointestinal disorders | 1/185 | 0/224 |
| Cholecystitis chronicHepatobiliary disorders | 1/185 | 0/224 |
| Ear infectionInfections and infestations | 1/185 | 0/224 |
| AsthmaRespiratory, thoracic and mediastinal disorders | 1/185 | 1/224 |
| AppendicitisInfections and infestations | 0/185 | 1/224 |
| COVID-19 pneumoniaInfections and infestations | 0/185 | 1/224 |
| Oral candidiasisInfections and infestations | 0/185 | 1/224 |
| ArthralgiaMusculoskeletal and connective tissue disorders | 0/185 | 1/224 |
| Endometrial cancer stage IVNeoplasms benign, malignant and unspecified (incl cysts and polyps) | 0/185 | 1/224 |
| Event | Standard of Care (SoC) | Digital System (DS) |
|---|---|---|
| COVID-19Infections and infestations | 15/185 | 6/224 |
| AsthmaRespiratory, thoracic and mediastinal disorders | 11/185 | 18/224 |
Intent-to-treat (ITT) analysis set included all randomized participants.
| Age, Continuous(years) | Standard of Care (SoC) | Digital System (DS) | Total |
|---|---|---|---|
| Mean | 46.7 ± 17.72 | 46.9 ± 18.36 | 46.8 ± 18.06 |
| Sex: Female, Male(Participants) | Standard of Care (SoC) | Digital System (DS) | Total |
|---|---|---|---|
| Female | 116 | 177 | 293 |
| Male | 69 | 65 | 134 |
| Ethnicity (NIH/OMB)(Participants) | Standard of Care (SoC) | Digital System (DS) | Total |
|---|---|---|---|
| Hispanic or Latino | 63 | 80 | 143 |
| Not Hispanic or Latino | 114 | 157 | 271 |
| Unknown or Not Reported | 8 | 5 | 13 |
| Race/Ethnicity, Customized(Participants) | Standard of Care (SoC) | Digital System (DS) | Total |
|---|---|---|---|
| White | 136 | 185 | 321 |
| Black or African American | 37 | 45 | 82 |
| Asian | 7 | 6 | 13 |
| American Indian or Alaska Native | 1 | 0 | 1 |
| Native Hawaiian or other Pacific Islander | 1 | 1 | 2 |
| Not reported | 2 | 4 | 6 |
| Other | 1 | 1 | 2 |
PDFs hosted by the registry, ClinicalTrials.gov.
Plan to share: Yes — Qualified researchers may request access to patient level data and related study documents including the study protocol and the statistical analysis plan. Requests will be reviewed for scientific merit, product approval status, and conflicts of interest. Patient level data will be de-identified and study documents will be redacted to protect the privacy of trial participants and to protect commercially confidential information. Please email USMedInfo@tevapharm.com to make your request.
Ran from Feb 2021 to primary completion in Mar 2022, 12 months.
Results were first posted in Mar 2023, 1 year after primary completion.
Of 66 industry-sponsored phase 4 interventional studies under Asthma, half reached primary completion within 21 months of starting (the median), counting those still running; a quarter within 9 and three quarters within 33. This study's 12 months is below that.
Counting every sponsor, half of 156 studies reached it within 24 months; a quarter within 11 and three quarters within 37.
How these figures are worked out, and which studies are left out of them.
This study is completed, as verified in Feb 2023. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Studies of the drugs tested here: Fluticasone · Salmeterol Xinafoate · Albuterol
Teva Branded Pharmaceutical Products R&D, Inc. →